Device Trial Radar · NCT07863739
CO₂ Laser With or Without Platelet-Rich Plasma for Genitourinary Syndrome of Menopause
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 1, 2023
Primary completion
Apr 1, 2025
Study completion Apr 1, 2025
Sponsor
- Lead sponsor
- National and Kapodistrian University of AthensAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated whether adding platelet-rich plasma (PRP) to fractional CO₂ laser treatment provides additional benefit for postmenopausal women with genitourinary syndrome of menopause (GSM). Participants received either fractional CO₂ laser treatment alone or fractional CO₂ laser combined with PRP injections. Both groups received three treatment sessions at 4-6-week intervals. The main outcome was the change in vaginal dryness after treatment. Other outcomes included vaginal symptoms, sexual function, quality of life, and measures of vaginal health. The study also evaluated the safety and tolerability of both treatments.
Conditions
- Genitourinary Syndrome of Menopause (GSM)
Interventions
Fractional CO₂ LaserDevice
Fractional laser treatment was performed using the DEKA DUOGlide GYN system (DEKA M.E.L.A., Florence, Italy), combining CO₂ (10,600 nm) and 1540 nm wavelengths. Three treatment sessions were performed at 4-6-week intervals.
Autologous Platelet-Rich Plasma (PRP)Biological
Autologous PRP was prepared from 40 mL of peripheral blood using the OMNIPLEX Gyno kit, yielding approximately 3 mL of PRP with a platelet concentration approximately nine times baseline. PRP was injected into predefined vaginal sites immediately after each laser treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Vaginal Dryness SeverityTime frame: Baseline to 1 month after the final treatment session
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexandra General Hospital
Athens, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.